[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634330":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":11,"responsibleParty":33,"collaborators":11,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":11,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":11},{"fullName":5,"class":6},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine","EXPERIMENTAL",null,[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Intranasal dexmedetomidine (100 µg total: 4 sprays, 25 µg\u002Fspray; Hengrui Medicine, China) self-administered preoperatively (\\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Intranasal water for injection (4 sprays, identical volume as nasal dexmedetomidine; Hengrui Medicine, China) self-administered preoperatively (\\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Mentying Ding, MD.","CONTACT","+86-15170375679","15170375679@163.com",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Xiangcai Ruan, MD, PhD","Professor","100634330","phase-2-minimizing-delirium-with-nasal-dexmedetomidine-induced-sleep-middies-100634330",false,"NCT07538284","MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES)","Minimizing Delirium With Nasal Dexmedetomidine-Induced Sleep in Older Patients Undergoing Major Abdominal Surgery: : a Randomized, Double-blind, Placebo-controlled Trial","MIDDIES","Inclusion Criteria:\n\n* Aged 65-90 years\n* Scheduled for a major abdominal surgery with estimated surgery time ≥ 2 hours\n\nExclusion Criteria:\n\n* Blind, deafness or the inability to speak mandarin\n* Allergy to dexmedetomidine.\n* Renal and liver failure requiring dialysis or Child-Pugh score \\> 5\n* Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)\n* Previous major abdominal or cardiac surgery within 1 year of surgical procedure\n* Chronic therapy with benzodiazepines and\u002For antipsychotics. Severe deficit due to structural or anoxic brain damage\n* Body weight \\\u003C 35 kg","ALL","65 Years","90 Years",{"count":49,"type":50},400,"ESTIMATED","INTERVENTIONAL",[53,54],"PHASE2","PHASE3","This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.",[57,58,59,60],"Major Abdominal Surgery","Postoperative Delirium (POD)","Sleep Disturbances","Intranasal Dexmedetomidine",[62,63],"dexmedetomidine","intranasal administration","NOT_YET_RECRUITING","2026-04-12",{"date":67,"type":68},"2026-04-20","ACTUAL",{"date":70,"type":50},"2026-05-01",{"date":72,"type":50},"2027-06-30",{"name":5,"class":6}]